Significant and durable clinical benefit from trastuzumab in 2 patients with HER2 ‐amplified salivary gland cancer and a review of the literature

ConclusionGiven the poor prognosis for salivary gland cancers and the limited treatment options upon recurrence or metastasis, patients should be tested for all classes of HER2 alterations. In cases with HER2 overexpression or activation, targeted therapies, such as trastuzumab are promising. © 2016 Wiley Periodicals, Head Neck, 2016

Source: Head and Neck - December 21, 2016 Category: ENT & OMF Authors: Lauren M. Thorpe, Alexa B. Schrock, Rachel L. Erlich, Vincent A. Miller, James Knost, Nguyet Le ‐Lindqwister, Srinivas Jujjavarapu, Siraj M. Ali, Jane J. Liu Tags: Case Report Source Type: research